Get a better understanding of cell avidity, why is it important and relevant to understand the mechanism of action through the latest publications, webinars, application notes and white papers
Sarah Tettamanti, PhD Tettamanti Center, Fondazione IRCCS San Gerardo dei Tintori
Dr. Marcela Maus, Associate Professor of Medicine Massachusetts General Hospital, Harvard Medical School
Dr. Rebecca Larson, PhD Graduate from Harvard University
Dr. Maria Themeli, Group Leader of Hematology Department at Amsterdam UMC Cancer Center Amsterdam
Prof. Mark Lowdell, Professor of Cell & Tissue Therapy at University College London and Chief Scientific Officer of INmune Bio, Inc
Prof. Carlos Fernandez de Larrea, Associate Professor of Medicine University of Barcelona
Dr. Will Singleterry, Director of Business Development at LUMICKS
Prof. Carlos Fernandez de Larrea Associate Professor of Medicine at University of Barcelona
Dr. Natalie Rufer Associate Professor at University of Lausanne
Dr. Maria Themeli Group Leader of Hematology Department at Amsterdam UMC Cancer Center Amsterdam
Dr. Marcela Maus Associate Professor at Harvard Medical School and Director of Cellular Immunotherapy at Massachusetts General Hospital
Natural killer (NK) cell-based immunotherapies have shown promise in cancer treatment, but their clinical efficacy is often limited by poor persistence and reduced functionality, especially post-cryopreservation….
Recent advances in T cell-based immunotherapies, such as checkpoint blockade and adoptive cellular therapy, have revolutionized cancer treatment. However, the tumor microenvironment (TME) remains a significant barrier, limiting the effectiveness of these therapies through several…
Next generation chimeric antigen receptor (CAR) T cell therapies holds the promise in providing a curative solution for solid tumors. Nonetheless, the significant clinical hurdle of on-target off-tumor toxicity (OTOT) remains a major impediment…
T cell receptor (TCR) engineered T-cell therapy shows tremendous potential in combating metastatic melanoma, synovial sarcoma and myeloma, as evidenced by numerous ongoing clinical trials….
Introducing the acoustic technology within the heart of our z-Movi
How to perform cell avidity analsis experiments in a mater of hours
Learn how the formation of an immune synaptic interface between T cells and tumor cells leads to activities required for T cell activation and cytokine release
Understanding the term “cell avidity” and how it fills the current scientific research gap
Open Email
Please include ‘Lakeview data analysis price inquiry’ in the Message box
Contact Us
Get exclusive news on the latest publications, product developments, events and breakthrough science.
By submitting the form you agree to LUMICKS' privacy policy. You can revoke your consent at any time.